N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming
PublisherIvyspring International Publisher
MetadataShow full item record
AbstractBackground: Drug resistance severely reduces treatment efficiency of chemotherapy and leads to poor prognosis. However, regulatory factors of chemoresistant cancer cells are largely unknown. Methods: The expression of estrogen receptor related receptors (ERRs) in chemoresistant cancer cells are checked. The roles of ERRγ in chemoresistance are confirmed by in vitro and in vivo studies. The mechanisms responsible for ERRγ-regulated expression of ABCB1 and CPT1B are investigated. Results: The expression of ERRγ is upregulated in chemoresistant cancer cells. Targeted inhibition of ERRγ restores the chemosensitivity. ERRγ can directly bind to the promoter of ABCB1 to increase its transcription. An elevated interaction between ERRγ and p65 in chemoresistant cells further strengthens transcription of ABCB1. Further, ERRγ can increase the fatty acid oxidation (FAO) in chemoresistant cells via regulation of CPT1B, the rate-limiting enzyme of FAO. The upregulated ERRγ in chemoresistant cancer cells might be due to increased levels of N6-methyladenosine (m6A) can trigger the splicing of precursor ESRRG mRNA. Conclusions: m6A induced ERRγ confers chemoresistance of cancer cells through upregulation of ABCB1 and CPT1B. Copyright The author(s).
SponsorsThis research was supported by the National Natural Science Foundation of China (Grant Nos. 81973343, 81673454, 81672608, 81871994, and 81701834), the Fundamental Research Funds for the Central Universities (Sun Yat-sen University) (Nos.19ykpy130 and 19ykzd24), the Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery (2019B030301005), the Guangdong Provincial Key Laboratory of Construction Foundation (No. 2017B030314030), the Guangdong Natural Science Foundation (2019B151502063), and the Guangzhou Science and Technology Planning Program (201902020018). CM Chiang's research was supported by US National Institutes of Health (CA103867), Cancer Prevention Research Institute of Texas (RP180349 and RP190077) and the Welch Foundation (I-1805).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85080868485&doi=10.7150%2fthno.40144&partnerID=40&md5=5df11f765b506373a8f1fa308be0e327; http://hdl.handle.net/10713/12242